Pharma BD Deal Intelligence
In April 2026 MeiraGTx (Nasdaq: MGTX) entered into an asset purchase agreement with Johnson & Johnson (Janssen) to re-acquire all global rights to botaretigene sparoparvovec (bota-vec), an AAV5-RPGR gene therapy for X-linked retinitis pigmentosa (XLRP) that MeiraGTx had originally developed and out-licensed to Janssen. MeiraGTx paid a one-time $25 million upfront cash payment; J&J is eligible for a single regulatory-and-commercial milestone tied to U.S. approval and U.S. sales, plus a royalty on global net sales beginning mid-2029. (MeiraGTx's deal-announcement release described the royalty as 'high double-digit' while its Q1 2026 results characterized it as 'mid-teens' — the precise rate is undisclosed/contested.) The hand-back followed the Phase 3 LUMEOS trial missing its primary visual-navigation endpoint in 2025; MeiraGTx intends to file BLA/MAA in the U.S., EU and Japan on the strength of secondary endpoint and safety data, targeting a potential 2027 launch. Separately and concurrently, MeiraGTx priced an underwritten offering of 11,111,111 ordinary shares at $9.00, raising ~$100 million gross to fund the program (the financing is distinct from the $25M asset purchase price).